Zandelisib (ME-401) 是一种 PI3K 抑制剂，选择性抑制 p110δ 的 IC50 值为 3.5 nM，详细信息请参考专利文献 WO2019183226 A1 中的化合物 1。Zandelisib 具有抗肿瘤作用。
货号:ajcx33804
CAS:1401436-95-0
分子式:C31H38F2N8O
分子量：576.68
溶解度:DMSO : 33.33 mg/mL (57.80 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC50 of 3.5 nM. Zandelisib functions as an antineoplastic[1][2].

Zandelisib inhibits PI3Ks with IC50s of 4, 976 nM, 605 nM, 817 nM and 3.5 nM for p110α, p110β, p110γ and p110δ, respectivey[1].

[1]. Daniel P. Gold, et al. Combination therapy. WO2019183226A1.
[2]. David Brown, et al. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases. WO2014055647A1.